Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 8;12:2040622321997259. doi: 10.1177/2040622321997259

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — KDM4C is upregulated in bone marrow tissue samples from AML patients and in the HL-60/A cell line. (a) Analysis of KDM4C expression level in AML based on TCGA (173 bone marrow tissue samples from AML patient) and GTEx (70 normal bone marrow samples) databases. (b) RT-qPCR detection of KDM4C expression in bone marrow tissue samples from 30 AML patients and 30 normal bone marrow samples, *comparison with normal group. (c) MTT assay to analyze HL-60 and HL-60/A viability after Ara-C treatment, *comparison with HL-60. (d) Flow cytometry to study the cell cycle of HL-60 and HL-60/A, *comparison with HL-60. (e) RT-qPCR to detect the expression of KDM4C in HL-60 and HL-60/A, *comparison with HL-60. (f) Western blot to detect the expression of KDM4C protein in HL-60 and HL-60/A cells, *comparison with HL-60. (g) Western blot to analyze the efficiency of KDM4C expression in HL-60/A, *comparison with HL-60/A oe-NC. (h) MTT assay to analyze HL-60/A cell viability after oe-KDM4C treatment, *p < 0.05 compared with oe-NC. (i) Flow cytometry to analyze the cell cycle after overexpression of KDM4C in HL-60/A, *comparison with HL-60/A oe-NC. Experiments were repeated three times. Data from two groups was compared by unpaired t-test.

AML, acute myeloid leukemia; Ara-C, cytarabine; NC, negative control; oe, overexpression; RT-qPCR, real-time quantitative polymerase chain reaction; TCGA, The Cancer Genome Atlas; GTEx, Genotype-Tissue Expression; MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.